SEC Form 4 · accession 0001875714-26-000009
Xeris Biopharma Holdings, Inc. · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven Pieper
Officer — See Remarks
Period of report
Aug 12, 2026
Accepted (ET)
Aug 12, 2026 · 4:44 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001867096
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 12, 2026 | S | 5,000 | $8.50 | D | 1,361,053 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.
Remarks
Chief Financial Officer